Rhucin BLA submission expected in 2012 as Phase III trial agreed
This article was originally published in Scrip
Pharming and Santarus have now reached agreement with the US FDA on the design of a Phase III trial of Rhucin (recombinant human C1 inhibitor), which will support a Biologics License Application (BLA) submission under the Special Protocol Assessment (SPA) process. "The study is still expected to be completed by the third quarter of 2012," the companies said.
You may also be interested in...
Danish firm Topotarget said it was 'very confident' that it will be able to raise its first milestone from partner, Spectrum Pharmaceuticals, by the third quarter as it reported that final top-line data confirm that the primary endpoint was met in the Phase II BELIEF trial investigating an intravenous formulation of the histone deacetylase (HDAC) inhibitor, belinostat, for peripheral T-cell lymphoma (PTCL).
AstraZeneca's Caprelsa (vandetanib) has become the first treatment to be approved for advanced medullary thyroid cancer (MTC) in Europe after being granted marketing authorisation by the European Commission.
Despite reporting positive weight loss data from the third of four Phase IIIa trials from the SCALE program investigating liraglutide (Victoza) for obesity Novo Nordisk has failed to dazzle analysts who have questioned the commercial potential of the drug in this arena.